8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 4, 2026·SEC
Cabaletta Bio, Inc.(CABA)Earnings, Financials & Key Ratios
CABA•NASDAQ
Price updated Jun 17, 2026
AboutCabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Show more
- Revenue$0
- EBITDA-$171M-38.2%
- Net Income-$168M-44.9%
- EPS (Diluted)-1.64+29.9%
- ROE-126.98%-112.9%
CABA Key Insights
Cabaletta Bio, Inc. (CABA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 38.2% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CABA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CABA Price & Volume
Cabaletta Bio, Inc. (CABA) stock price & volume — 10-year historical chart
Loading chart...
CABA Growth Metrics
Cabaletta Bio, Inc. (CABA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-38.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM23.05%
Return on Capital
10 Years-51.02%
5 Years-64.3%
3 Years-77.59%
Last Year-126.23%
CABA Recent Earnings
Cabaletta Bio, Inc. (CABA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.39+4.9%
$0.41
Rev
—
$2M
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$0.40+11.1%
$0.45
Rev
—
$833,333
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.44+10.2%
$0.49
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.73-2.8%
$0.71
Rev
—
$4M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.39vs $0.41+4.9% | —vs $2M |
| Q2 2026 | Mar 23, 2026 | $0.40vs $0.45+11.1% | —vs $833,333 |
| Q4 2025 | Nov 10, 2025 | $0.44vs $0.49+10.2% | — |
| Q3 2025 | Aug 7, 2025 | $0.73vs $0.71-2.8% | —vs $4M |
Based on last 12 quarters of dataView full earnings history →
CABA Peer Comparison
Cabaletta Bio, Inc. (CABA) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.34B | 89.90 | -24.36 | -16.72% | -6.12% | -25.02% | 0.05 | |
 IMVT | 7.13B | 34.71 | -12.53 | -68.16% | 0.00 | |||
 ARQT | 3.28B | 26.22 | -201.69 | 91.34% | -0.57% | -1.41% | 0.03 | |
 ROIV | 22.44B | 31.20 | -72.56 | -71.57% | -36.29% | -6.03% | 0.02 | |
 PRAX | 7.8B | 270.01 | -20.03 | -100% | -43.02% | 0.00 | ||
 TGTX | 7.88B | 51.50 | 18.59 | 87.32% | 65.95% | 87.36% | 0.40 | |
 BEAM | 3.34B | 32.48 | -40.10 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 5.12B | 53.09 | -8.21 | -89.97% | -138.57% | -30.88% | 0.21 |
Compare CABA vs Peers
Cabaletta Bio, Inc. (CABA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CABA Income Statement
Cabaletta Bio, Inc. (CABA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | 250K | 6.19M | 18.68M | 33.83M | 46.31M | 54.14M | 74.66M | 125.14M | 172.24M | 179.4M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 250K | 1.73M | 7.01M | 12.46M | 13.82M | 14.84M | 19.24M | 27.94M | 29.57M | 28.39M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 0 | 4.47M | 11.67M | 21.38M | 32.49M | 39.3M | 55.42M | 97.2M | 142.67M | 151.01M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -250K▲ 0% | -6.19M▼ 2377.2% | -18.68M▼ 201.7% | -33.83M▼ 81.1% | -46.31M▼ 36.9% | -54.14M▼ 16.9% | -74.66M▼ 37.9% | -125.14M▼ 67.6% | -172.24M▼ 37.6% | -179.4M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -2377.2% | -201.68% | -81.09% | -36.89% | -16.9% | -37.9% | -67.61% | -37.64% | - |
EBITDA | 83.33K | 0 | -18.58M | -33.48M | -45.58M | -52.96M | -73.23M | -123.43M | -170.59M | -177.9M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -100% | - | -80.2% | -36.14% | -16.19% | -38.28% | -68.54% | -38.21% | -34.32% |
D&A (Non-Cash Add-back) | 333.33K | 6.19M | 104K | 354K | 733K | 1.18M | 1.43M | 1.71M | 1.65M | 1.5M |
EBIT | -250K | -12.2M | -18.68M | -33.34M | -46.31M | -54.14M | -67.67M | -115.12M | -165.85M | -173.08M |
Net Interest Income | 0 | 0 | 1.74M | 494K | 24K | 1.16M | 6.99M | 9.28M | 4.03M | 3.27M |
Interest Income | 0 | 235K | 1.74M | 494K | 24K | 1.16M | 6.99M | 10.03M | 6.03M | 5.62M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 748K | 2M | 2.35M |
Other Income/Expense | 0 | -6.01M | 1.74M | 494K | 24K | 1.16M | 6.99M | 9.28M | 4.38M | 3.97M |
Pretax Income | -250K▲ 0% | -12.2M▼ 4780.8% | -16.94M▼ 38.9% | -33.34M▼ 96.8% | -46.29M▼ 38.8% | -52.98M▼ 14.4% | -67.67M▼ 27.7% | -115.86M▼ 71.2% | -167.86M▼ 44.9% | -175.43M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -250K▲ 0% | -12.2M▼ 4780.8% | -16.94M▼ 38.9% | -33.34M▼ 96.8% | -46.29M▼ 38.8% | -52.98M▼ 14.4% | -67.67M▼ 27.7% | -115.86M▼ 71.2% | -167.86M▼ 44.9% | -175.43M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -4780.8% | -38.85% | -96.77% | -38.84% | -14.44% | -27.75% | -71.21% | -44.87% | -38.39% |
Net Income (Continuing) | -250K | -12.2M | -16.94M | -33.34M | -46.29M | -52.98M | -67.67M | -115.86M | -167.86M | -175.43M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.01▲ 0% | -0.84▼ 7976.9% | -4.07▼ 384.5% | -1.44▲ 64.6% | -1.80▼ 25.0% | -1.81▼ 0.6% | -1.65▲ 8.8% | -2.34▼ 41.8% | -1.64▲ 29.9% | -1.57▲ 0% |
EPS Growth % | - | -7976.92% | -384.52% | 64.62% | -25% | -0.56% | 8.84% | -41.82% | 29.91% | 23.05% |
EPS (Basic) | -0.01 | -0.84 | -4.07 | -1.44 | -1.80 | -1.81 | -1.65 | -2.34 | -1.64 | - |
Diluted Shares Outstanding | 24.03M | 14.51M | 5.47M | 23.14M | 25.74M | 29.34M | 40.95M | 49.47M | 102.26M | 112.03M |
Basic Shares Outstanding | 24.03M | 14.51M | 4.16M | 23.14M | 25.74M | 29.34M | 40.95M | 49.52M | 102.26M | 112.03M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CABA Balance Sheet
Cabaletta Bio, Inc. (CABA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1K | 33.99M | 140.55M | 113.53M | 124.54M | 108.83M | 244.49M | 166.68M | 138.87M | 122.32M |
Cash & Short-Term Investments | 1K | 33.02M | 136.2M | 108.66M | 122.22M | 106.55M | 241.25M | 163.96M | 133.6M | 116.64M |
Cash Only | 1K | 33.02M | 136.2M | 101.43M | 122.22M | 81.61M | 193.24M | 163.96M | 82.98M | 116.64M |
Short-Term Investments | 0 | 0 | 0 | 7.23M | 0 | 24.94M | 48.01M | 0 | 50.62M | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 2.76M | 1.85M | 1.97M | 2.29M | 0 | 2.71M | 5.27M | 5.68M |
Total Non-Current Assets | 0 | 180K | 916K | 1.19M | 1.79M | 8.13M | 9.16M | 22.31M | 26.21M | 25.83M |
Property, Plant & Equipment | 0 | 0 | 815K | 890K | 1.44M | 7.57M | 7.45M | 16.08M | 21.05M | 20.56M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 180K | 101K | 299K | 357K | 565K | 1.71M | 6.23M | 5.16M | 5.27M |
Total Assets | 1K▲ 0% | 34.17M▲ 3417300.0% | 141.47M▲ 314.0% | 114.72M▼ 18.9% | 126.34M▲ 10.1% | 116.97M▼ 7.4% | 253.65M▲ 116.9% | 185.05M▼ 27.0% | 165.08M▼ 10.8% | 148.15M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 3417300% | 313.96% | -18.9% | 10.12% | -7.42% | 116.85% | -27.05% | -10.79% | -24.99% |
Total Current Liabilities | 250K | 943K | 3.15M | 5.18M | 8.38M | 9.49M | 15.99M | 27.09M | 50.15M | 41.51M |
Accounts Payable | 189K | 603K | 920K | 1.24M | 2.33M | 2.46M | 4.55M | 4.92M | 6.64M | 6.38M |
Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.22M | 23.12M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12K | 219K | 705K | 38K | 3.07M | 1.33M | 40K | 8.36M | 19.3M | 8.37M |
Current Ratio | 0.00x | 36.05x | 44.66x | 21.92x | 14.86x | 11.47x | 15.29x | 6.15x | 2.77x | 2.95x |
Quick Ratio | 0.00x | 36.05x | 44.66x | 21.92x | 14.86x | 11.47x | 15.29x | 6.15x | 2.77x | 2.95x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 189K | 43.92M | 920K | 0 | 0 | 2.96M | 1.46M | 5.63M | 2.88M | 3.33M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.88M | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 2.96M | 1.46M | 5.63M | 0 | 7.81M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 250K | 44.86M | 3.15M | 5.18M | 8.38M | 12.45M | 17.45M | 32.71M | 53.03M | 44.84M |
Total Debt | 0 | 43.92M | 0 | 0 | 0 | 5.14M | 5.02M | 15.6M | 27.1M | 26.45M |
Net Debt | -1K | 10.9M | -136.2M | -101.43M | -122.22M | -76.47M | -188.22M | -148.36M | -55.88M | -90.19M |
Debt / Equity | - | - | - | - | - | 0.05x | 0.02x | 0.10x | 0.24x | 0.26x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.15x |
Net Debt / EBITDA | -0.01x | - | - | - | - | - | - | - | - | 0.51x |
Interest Coverage | - | - | - | - | - | - | - | -153.90x | -82.76x | -73.78x |
Total Equity | -249K▲ 0% | -10.69M▼ 4193.2% | 138.32M▲ 1393.9% | 109.54M▼ 20.8% | 117.96M▲ 7.7% | 104.52M▼ 11.4% | 236.2M▲ 126.0% | 152.34M▼ 35.5% | 112.05M▼ 26.4% | 103.31M▲ 0% |
Equity Growth % | - | -4193.17% | 1393.93% | -20.8% | 7.68% | -11.39% | 125.98% | -35.51% | -26.44% | -71.96% |
Book Value per Share | -0.01 | -0.74 | 25.29 | 4.73 | 4.58 | 3.56 | 5.77 | 3.08 | 1.10 | 0.92 |
Total Shareholders' Equity | -249K | -10.69M | 138.32M | 109.54M | 117.96M | 104.52M | 236.2M | 152.34M | 112.05M | 103.31M |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 1K | 1K |
Retained Earnings | -250K | -12.45M | -32.96M | -66.3M | -112.59M | -165.56M | -233.24M | -349.1M | -516.96M | -560.47M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 6K | 0 | -47K | 39K | 0 | 25K | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CABA Cash Flow Statement
Cabaletta Bio, Inc. (CABA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 0 | -4.66M | -16.05M | -26.77M | -34.11M | -46.38M | -53.55M | -88.22M | -131.08M | -142.84M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | - | -244.24% | -66.84% | -27.41% | -35.98% | -15.46% | -64.75% | -48.58% | -207.19% |
Net Income | -333.33K | -12.2M | -16.94M | -33.34M | -46.29M | -52.98M | -67.67M | -115.86M | -167.86M | -175.43M |
Depreciation & Amortization | 0 | 0 | 104K | 354K | 733K | 1.18M | 1.43M | 1.71M | 1.65M | 1.5M |
Stock-Based Compensation | 0 | 606K | 2.3M | 4.39M | 5.8M | 6.9M | 11.34M | 19.46M | 20.94M | 15.78M |
Deferred Taxes | 0 | 0 | -2.26M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 252K | 7.4M | 2.26M | 119K | 62K | 2.82M | 1.26M | 4.86M | 14.57M | 22.02M |
Working Capital Changes | 81.33K | -464K | -1.51M | 1.71M | 5.58M | -4.3M | 101K | 1.61M | -379K | -6.7M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 234K | 246K | 555K | 975K | -28K | 1.68M | 1.01M | 1.55M | -310K |
Cash from Investing | 0 | 0 | -693K | -7.98M | 6M | -27.22M | -22.45M | 47.29M | -50.27M | 1.48M |
Capital Expenditures | 0 | 0 | -693K | -635K | -1.17M | -2.45M | -687K | -2.21M | -1.23M | -444K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 7.35K | 0 | 24.76K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -7.35K | 0 | -24.76K | 0 | 0 | 0 | 0 |
Cash from Financing | 1.33K | 37.68M | 119.92M | -24K | 48.9M | 32.98M | 187.63M | 11.68M | 100.35M | 126.17M |
Debt Issued (Net) | 0 | 12.54M | 0 | 0 | 0 | 0 | 0 | -897K | -6.26M | -3.72M |
Equity Issued (Net) | 0 | 25.31M | 121.21M | -192K | 48.25M | 32.85M | 185.2M | 10.88M | 106.61M | 135.94M |
Dividends Paid | 0 | 0 | -10.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -169K | 0 | -192K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.33K | -169K | 8.8M | 168K | 650K | 127K | 2.43M | 1.7M | 0 | -6.05M |
Net Change in Cash | 1.33K▲ 0% | 33.02M▲ 2476719.2% | 103.19M▲ 212.5% | -34.77M▼ 133.7% | 20.79M▲ 159.8% | -40.62M▼ 295.3% | 111.63M▲ 374.9% | -29.28M▼ 126.2% | -80.98M▼ 176.6% | -15.2M▲ 0% |
Free Cash Flow | 0▲ 0% | -4.66M▲ 0% | -16.74M▼ 259.1% | -27.41M▼ 63.7% | -35.27M▼ 28.7% | -48.83M▼ 38.4% | -54.24M▼ 11.1% | -90.43M▼ 66.7% | -132.31M▼ 46.3% | -143.28M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | - | -259.11% | -63.73% | -28.72% | -38.44% | -11.06% | -66.74% | -46.31% | -47.38% |
FCF per Share | - | -0.32 | -3.06 | -1.18 | -1.37 | -1.66 | -1.32 | -1.83 | -1.29 | -1.28 |
FCF Conversion (FCF/Net Income) | - | 0.38x | 0.95x | 0.80x | 0.74x | 0.88x | 0.79x | 0.76x | 0.78x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -208K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CABA Key Ratios
Cabaletta Bio, Inc. (CABA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -26.55% | -26.9% | -40.69% | -47.62% | -39.72% | -59.64% | -126.98% | -131.58% |
Return on Invested Capital (ROIC) | - | -1202.25% | -495.99% | -1804.87% | -341.43% | -147.3% | -361.32% | -429.6% | -231.9% |
Debt / Equity | - | - | - | - | 0.05x | 0.02x | 0.10x | 0.24x | 0.26x |
Interest Coverage | - | - | - | - | - | - | -153.90x | -82.76x | -73.78x |
FCF Conversion | 0.38x | 0.95x | 0.80x | 0.74x | 0.88x | 0.79x | 0.76x | 0.78x | 0.82x |
Related:CABA Dividend History·CABA Revenue History·CABA Price History·CABA P/E History·CABA Financial Ratios·CABA Institutional Holders
CABA SEC Filings & Documents
Cabaletta Bio, Inc. (CABA) SEC filings — annual & quarterly reports (10-K, 10-Q)
CABA Frequently Asked Questions
Cabaletta Bio, Inc. (CABA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cabaletta Bio, Inc. (CABA) grew revenue by 0.0% over the past year. Growth has been modest.
Cabaletta Bio, Inc. (CABA) reported a net loss of $175.4M for fiscal year 2025.
Dividend & Returns
Cabaletta Bio, Inc. (CABA) has a return on equity (ROE) of -127.0%. Negative ROE indicates the company is unprofitable.
Cabaletta Bio, Inc. (CABA) had negative free cash flow of $143.3M in fiscal year 2025, likely due to heavy capital investments.